Prostate Cell News Volume 11.38 | Oct 9 2020

    0
    81







    2020-10-09 | PCN 11.38


    Prostate Cell News by STEMCELL Technologies
    Vol. 11.38 – 9 October, 2020
    TOP STORY

    Estrogen Receptor β Regulates AKT Activity through Up-Regulation of INPP4B and Inhibits Migration of Prostate Cancer Cell Line PC-3

    Investigators found that in prostate cancer (PCa), samples from men treated with androgen deprivation therapy, ERβ, and inositol-polyphosphate 4-phosphatase type II (INPP4B) expression were maintained in some samples. To investigate the role of ERβ1 in regulation of INPPB, they engineered the highly metastatic PCa cell line, PC3, to express ERβ1.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Download an e-book covering the evolution of organoids, from their development to updated applications and future outlooks.
    PUBLICATIONSRanked by the impact factor of the journal

    De Novo Induction of Lineage Plasticity from Human Prostate Luminal Epithelial Cells by Activated AKT1 and C-Myc

    Scientists demonstrated de novo neuroendocrine differentiation of the human prostate luminal epithelial cells induced by caAKT1 and c-Myc and revealed an impact of cellular status on initiation of lineage plasticity.
    [Oncogene]

    Abstract

    Long Noncoding RNA Hotair Regulates the Invasion and Metastasis of Prostate Cancer by Targeting hepaCAM

    The authors demonstrated that HOX transcript antisense RNA (HOTAIR) promoted invasion and metastasis of prostate cancer by decreasing the inhibitory effect of hepaCAM on MAPK signaling.
    [British Journal of Cancer]

    Full Article

    In Vivo Imaging of Long-Term Accumulation of Cancer-Derived Exosomes Using a BRET-Based Reporter

    Transplantation of CD63-Antares2-expressing prostate cancer cells into mice allowed determining the amount of cancer-derived exosomes released from primary tumors into the bloodstream and visualizing the long-term homing behavior of exosomes to their target organs or tissues.
    [Scientific Reports]

    Full Article

    Blood-Based Gene Expression Signature Associated with Metastatic Castrate-Resistant Prostate Cancer Patient Response to Abiraterone Plus Prednisone or Enzalutamide

    Researchers utilized baseline blood samples to identify metastatic castrate-resistant prostate cancer patients most likely to benefit from abiraterone plus prednisone (AAP) or enzalutamide.
    [Prostate Cancer and Prostatic Diseases]

    Abstract

    Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Response Reverses Immunotherapy-Resistance in Prostate Tumors by Inducing a T-Cell Inflamed Microenvironment

    Oncolytic virus therapy can potentially overcome resistance to immunotherapy in prostate cancers by transforming cold tumors into ‘hot’, immune cell-infiltrated tumors. Scientists investigated whether the combination of intratumoral oncolytic reovirus, followed by targeted blockade of PD-1 checkpoint inhibition and/or the immunomodulatory CD73/Adenosine system could enhance anti-tumor immunity.
    [Molecular Therapy-Oncolytics]

    AbstractGraphical Abstract

    Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer

    Laboratory studies were carried out in human metastatic castrate-resistant prostate cancer organoid cultures, prostate cancer cell lines, and mouse xenograft models. Epigenetic studies were carried out in a rapid autopsy cohort.
    [JCO Precision Oncology]

    Abstract

    View tips on how to organize your lab bench space.
    REVIEWS

    Emerging Role of Tumor Cell Plasticity in Modifying Therapeutic Response

    Resistance to cancer therapy is a major barrier to cancer management. Conventional views have proposed that acquisition of resistance may result from genetic mutations. However, accumulating evidence implicates a key role of non-mutational resistance mechanisms underlying drug tolerance, the latter of which is the focus that is discussed here.
    [Signal Transduction and Targeted Therapy]

    Full Article

    INDUSTRY AND POLICY NEWS

    Lantheus Holdings Submits New Drug Application to the US FDA for PyLâ„¢ (18F-DCFPyL), a PSMA-Targeted Prostate Cancer Imaging Agent

    Lantheus Holdings, Inc. has announced the submission of a New Drug Application to the US FDA for PyLâ„¢, a prostate specific membrane antigen-targeted positron emission tomography imaging agent for prostate cancer.
    [Lantheus Holdings, Inc.]

    Press Release

    FEATURED EVENT

    The Evolving Tumor Microenvironment In Cancer Progression: Mechanisms And Emerging Therapeutic Opportunities

    January 9 – January 12, 2021
    Lake Buena Vista, Florida, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Prostate Cancer Research

    City of Hope – Duarte, California, United States

    Postdoctoral Position – Clinical AI and Data Science

    University of Southern Denmark – Odense M, Denmark

    Faculty Position – Cancer Biology

    University of Texas Southwestern Medical Center – Dallas, Texas, United States

    Postdoctoral Fellow – Epigenomics in Breast and Prostate Cancer

    Princess Margaret Cancer Center – Toronto, Ontario, Canada

    Research Associate – Stem Cell Differentiation and Cancer Initiation

    University of Miami – Miami, Florida, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Prostate Cell News Twitter